

Following FDA warning, Jubilant resolves quality issues

01 March 2014 | News | By BioSpectrum Bureau

Following FDA warning, Jubilant resolves quality issues



Jubilant Life Sciences has received a communication from the U.S. Food and Drug Administration (FDA), classifying its pharmaceutical manufacturing facility at Montreal, Canada as 'Acceptable'. The company announced the same on February 28, 2014.

"This resolves all issues raised by the FDA on the facility in February 2013 and subsequent communications. The development follows completion of FDA's review of the Company's responses post the February letter and the subsequent re-inspection conducted at Jubilant's Montreal facility in September, 2013. This development successfully resolves the FDA issues at our Montreal facility," mentioned the statement from the Jubilant.